medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2014, Number 1

<< Back

Rev Mex Med Transfus 2014; 7 (1)

Reflections about blood safety in Mexico

Novelo GB, Benítez AG

Language: Spanish
References: 60
Page: 45-50
PDF size: 415.81 Kb.


ABSTRACT

in December 1982, health and regulatory failures that hit the security system of Blood Banks worldwide were demonstrated. The international regulation at a date shows an important improvement and the laboratory tests are more specific and has more specificity, however, the physical medical examination have not yet improve. Unfortunately these developments are not reflected in the national legislation, significantly violating the right of patients requiring transfusion. In the present work are discussed progress in the detection of HIV in the blood banks using different strategies, also some points of Mexican transfusion safety rules are reviewed.


REFERENCES

  1. Evatt BL. The tragic history of AIDS in the hemophilia population, 1982–1984. J Thromb Haemost 2006;4: 2295–301.

  2. Sepulveda-Amor J, del Río-Zolezzi A, Valdespino Gómez JL, García-García Ma de L, Velázquez-Velázquez L, et al. La estrategia de prevención de la transmisión del VIH/SIDA a través de la sangre y sus derivados en México. Salud Pública de México. 1995;37 (6):624-635.

  3. Norma Oficial Mexicana 003-SSA2-1993 “Para la Disposición de Sangre y sus Componentes con Fines Terapéuticos”, publicada el 8 de diciembre de 1993 en el Diario Oficial de la Federación.

  4. Bruhn R, Lelie N, Custer B, Busch M, Kleinman S; International NAT Study Group. Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion. 2013 ;53 (10 Pt 2):2399-412

  5. Sánchez-Guerrero SA. La seguridad de la trasfusión sanguínea en México. Medicina Universitaria 2010; 12(46):79-‐83.

  6. El VIH/SIDA en México, 2009. Centro Nacional para la Prevención y Control del SIDA (CENSIDA) © 2009, CENSIDA 1ª Ed. México.

  7. Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res. 2011;3:37-46.

  8. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011;33 (9):1268-80.

  9. Norma Oficial Mexicana 253-SSA1-2012 “Para la Disposición de Sangre y sus Componentes con Fines Terapéuticos” fue publicada en el Diario Oficial de la Federación en octubre de 2012.

  10. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm345617.htm

  11. Bonder A and Nezam HA. Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C . Clinical Gastroenterology and Hepatology. 2013;11(3): 309-310.

  12. Kaz´mierczak J, Pawełczyk A, Caraballo-Cortes K, Radkowski M. Arch. Immunol. Seronegative Hepatitis C Virus Infection Ther. Exp. 2014;62:145–151.

  13. Virginia AM. On behalf of the U.S. Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement.Ann Intern Med. 2013; 159:349-357.

  14. http://www.cdc.gov/hepatitis/hcv/labtesting.htm

  15. John I. Allen, The Hepatitis C Task Force. Hepatitis C Screening: Summary of Recommendations From the Clinical Decision Tool. Gastroenterology . 2013; 145 (5);1146-1149.

  16. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. MMWR. 2013; 62(18):362-365.

  17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology. 2014; 60: 392–420.

  18. Recommendations for Testing, Managing and Treating Hepatitis C en: http://www.hcvguidelines.org

  19. Lyon Conference Report. Paper presented at: Joint WHO-CDC Conference on Health Laboratory Quality Systems. Lyon, France: 2008. WHO/CDC.

  20. Ullrich SE Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers. J Invest Dermatol 1991;96(3):303-308.

  21. Luban NL. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol. 2001;38(4);Suppl 11:34-45.

  22. Grass JA1, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood. 1998 Mar 15;91 (6):2180-2188.

  23. Grass JA1, Wafa T, Reames A, Wages D, Corash L, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93 (9):3140-3147.

  24. Corash L and Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplantation .2004; 33: 1–7.

  25. Schlenke P. Protection against Transfusion-Associated Graft-versus-Host Disease in Blood Transfusion: Is Gamma-Irradiation the Only Answer? . Transfus Med Hemother. 2004;31:24–31.

  26. Mintz PD and Wehrli G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplantation. 2009; 44, 205–211.

  27. Fast LD. Developments in the prevention of transfusion-associated graft-versus-host disease. British Journal of Haematology.2012; 158: 563–568.

  28. http://www.jornada.unam.mx/2013/02/07/ls-entrevista.htlm

  29. Franklin IM. Is there a right to donate blood? Patiente Rights; donor responsibilities. Transfus Med. 2007;17(3):161-168.

  30. Brooks JP. The rights of blood recipients should supersede any asserted rights of blood donors. Vox Sang. 2004;87 (4):280-286.

  31. Evatt BL. The tragic history of AIDS in the hemophilia population, 1982–1984. J Thromb Haemost 2006;4: 2295–301.

  32. Sepulveda-Amor J, del Río-Zolezzi A, Valdespino Gómez JL, García-García Ma de L, Velázquez-Velázquez L, et al. La estrategia de prevención de la transmisión del VIH/SIDA a través de la sangre y sus derivados en México. Salud Pública de México. 1995;37 (6):624-635.

  33. Norma Oficial Mexicana 003-SSA2-1993 “Para la Disposición de Sangre y sus Componentes con Fines Terapéuticos”, publicada el 8 de diciembre de 1993 en el Diario Oficial de la Federación.

  34. Bruhn R, Lelie N, Custer B, Busch M, Kleinman S; International NAT Study Group. Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion. 2013 ;53 (10 Pt 2):2399-412

  35. Sánchez-Guerrero SA. La seguridad de la trasfusión sanguínea en México. Medicina Universitaria 2010; 12(46):79-‐83.

  36. El VIH/SIDA en México, 2009. Centro Nacional para la Prevención y Control del SIDA (CENSIDA) © 2009, CENSIDA 1ª Ed. México.

  37. Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res. 2011;3:37-46.

  38. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011;33 (9):1268-80.

  39. Norma Oficial Mexicana 253-SSA1-2012 “Para la Disposición de Sangre y sus Componentes con Fines Terapéuticos” fue publicada en el Diario Oficial de la Federación en octubre de 2012.

  40. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm345617.htm

  41. Bonder A and Nezam HA. Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C . Clinical Gastroenterology and Hepatology. 2013;11(3): 309-310.

  42. Kaz´mierczak J, Pawełczyk A, Caraballo-Cortes K, Radkowski M. Arch. Immunol. Seronegative Hepatitis C Virus Infection Ther. Exp. 2014;62:145–151.

  43. Virginia AM. On behalf of the U.S. Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement.Ann Intern Med. 2013; 159:349-357.

  44. http://www.cdc.gov/hepatitis/hcv/labtesting.htm

  45. John I. Allen, The Hepatitis C Task Force. Hepatitis C Screening: Summary of Recommendations From the Clinical Decision Tool. Gastroenterology . 2013; 145 (5);1146-1149.

  46. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. MMWR. 2013; 62(18):362-365.

  47. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. Journal of Hepatology. 2014; 60: 392–420.

  48. Recommendations for Testing, Managing and Treating Hepatitis C en: http://www.hcvguidelines.org

  49. Lyon Conference Report. Paper presented at: Joint WHO-CDC Conference on Health Laboratory Quality Systems. Lyon, France: 2008. WHO/CDC.

  50. Ullrich SE Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers. J Invest Dermatol 1991;96(3):303-308.

  51. Luban NL. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol. 2001;38(4);Suppl 11:34-45.

  52. Grass JA1, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood. 1998 Mar 15;91 (6):2180-2188.

  53. Grass JA1, Wafa T, Reames A, Wages D, Corash L, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93 (9):3140-3147.

  54. Corash L and Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplantation .2004; 33: 1–7.

  55. Schlenke P. Protection against Transfusion-Associated Graft-versus-Host Disease in Blood Transfusion: Is Gamma-Irradiation the Only Answer? . Transfus Med Hemother. 2004;31:24–31.

  56. Mintz PD and Wehrli G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplantation. 2009; 44, 205–211.

  57. Fast LD. Developments in the prevention of transfusion-associated graft-versus-host disease. British Journal of Haematology.2012; 158: 563–568.

  58. http://www.jornada.unam.mx/2013/02/07/ls-entrevista.htlm

  59. Franklin IM. Is there a right to donate blood? Patiente Rights; donor responsibilities. Transfus Med. 2007;17(3):161-168.

  60. Brooks JP. The rights of blood recipients should supersede any asserted rights of blood donors. Vox Sang. 2004;87 (4):280-286.




2020     |     www.medigraphic.com